Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database-Reference-Cited by-同舟云学术

Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological database

Published:2021-08 Issue:11 Volume:13 Page:905-916
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Casarotto Emilie¹²,Chandwani Sheenu³,Mortier Laurent⁴,Dereure Olivier⁵,Dutriaux Caroline⁶,Dalac Sophie⁷,Scherrer Emilie⁸,Lévy-Bachelot Laurie¹,Verdoni Laetitia¹,Farge Gaëlle¹,Allayous Clara⁹,Oriano Bastien⁹,Dalle Stéphane¹⁰,Lebbé Céleste¹¹

Affiliation:

1. MSD France, Puteaux, France

2. Current affiliation: Ividata Life Sciences, Levallois Perret, France

3. Merck & Co., Inc., Kenilworth, NJ 07033, USA

4. Department of Dermatology, CHRU de Lille, University of Lille, ONCO-THAI INSERM, Lille, U1189, France

5. Department of Dermatology, University Hospital of Montpellier, Montpellier, France

6. Department of Dermatology, Bordeaux Saint-André Hospital, Bordeaux, France

7. Department of Dermatology, University Hospital of Dijon, Dijon, France

8. MSD, London, UK

9. Department of Dermatology, AP-HP Hôpital Saint Louis, F-75010 Paris, France

10. Department of Dermatology, Hospices Civils de Lyon, Cancer Research Center of Lyon, Pierre-Bénite, France

11. Université de Paris, Department of Dermatology, AP-HP Hôpital Saint Louis, F-75010 Paris, France; INSERM U976

Abstract

Aim: To describe real-world pembrolizumab administration and outcomes for advanced melanoma in France. Materials & methods: Using the MelBase longitudinal database, this multicenter historical-prospective study examined treatment and outcomes of patients with nonuveal, unresectable stage III/IV melanoma initiating pembrolizumab from April 2016 to September 2017, with follow-up to September 2019. Kaplan–Meier time-to-event analyses were conducted. Results: Of 223 patients (median age 67; 51% men), 134 (60%), 36 (16%) and 53 (24%) initiated pembrolizumab in first-, second- and third-line, respectively. Median overall survival (months) was 32.6 (95% CI: 20.3–not reached [NR]), 14.4 (8.6–NR) and 9.3 (6.4–NR), respectively. Best real-world tumor response of complete or partial response was recorded for 49, 39 and 26% of patients, respectively. Conclusion: Study results support benefits of pembrolizumab therapy for advanced melanoma.

Funder

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2021-0077

Reference28 articles.

1. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2. Participation in Cancer Clinical Trials

3. Using oncology real-world evidence for quality improvement and discovery: the case for ASCO's CancerLinQ

4. Opportunities and challenges in leveraging electronic health record data in oncology

5. The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real‐World Outcomes of Inoperable and Metastatic Cutaneous Head and Neck Melanoma Patients;The Laryngoscope;2024-01-17